News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Gunsagar Gulati: Two extraordinary papers released on BioRxiv
Photo from Gunsagar Gulati/X
Jul 31, 2024, 11:17

Gunsagar Gulati: Two extraordinary papers released on BioRxiv

Gunsagar Gulati, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X about two recent articles, commenting:

“Two extraordinary papers released today on BioRxiv:

  1. Mechanism behind cardiac benefit from SGLT2i, The Arany lab.
  2. Novel strategy for drugging P53-mutant cancers, William Gibson.

It’s an exciting time to be in physician-science!”

SGLT2 inhibitors activate pantothenate kinase in the human heart

Authors: Nicholas Forelli, Deborah Eaton, Jiten Patel, Caitlyn Bowman, Ryo Kawakami, Ivan Kuznetsov, Kristina Li, Claire Brady, Kenneth Bedi, Yijun Yang, Kaustubh Koya, Emily Megill, Daniel Kanter, Louis Smith, Gregory Bowman, Nathaniel Snyder, Jonathan Edwards, Kenneth Margulies, Zoltan Arany.

Gunsagar Gulati

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Authors: Ananthan Sadagopan, Nicholas Garaffo, Heng-Jui Chang, Stuart Schreiber, Matthew Meyerson, William Gibson.

Gunsagar Gulati

Source: Gunsagar Gulati/X

Ananthan Sadagopan bioRxiv Caitlyn Bowman cancer Claire Brady Dana-Farber Cancer Institute Deborah Eaton Gunsagar Gulati Heng-Jui Chang Ivan Kuznetsov Jiten Patel Kenneth Bedi Kristina Li Matthew Meyerson Nicholas Forelli Nicholas Garaffo OncoDaily Oncology p53 P53-mutant cancers Ryo Kawakami SGLT2i Stuart Schreiber The Arany lab William Gibson Yijun Yang
Special Coverage
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe
Blog
Dec 21, 2024, 19:18
The Institute of Cancer Research's annual report for 2023-2024